HCC study

Study name:

A Randomized Phase 2 Study of Casdozokitug in Combination with Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Eligibility:

Unresectable locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology

Treatment 1:

Casdozokitug in Combination with Toripalimab Plus Bevacizumab

Treatment 2:

Toripalimab Plus Bevacizumab

Personal Data Disclosure Disclaimer: We may collect, use, and disclose your personal data in accordance with the Personal Data (Privacy) Ordinance. Your information will be handled with care and only used for the purposes specified at the time of collection.